Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.51 |
| ▸ | RARG | P13631 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | GOT1 | P17174 | 1/20 | 0.51 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31482681 | 1.00 | RARA (0.51) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL3314599 | 0.88 | KMT2A (0.43) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL13687830 | 0.87 | RARB (0.67) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL10014913 | 0.87 | RARA (0.49) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL5828879 | 0.85 | RARA (0.44) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL20121984 | 0.82 | RARA (0.37) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL645476 | 0.82 | RARA (0.44) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL852174 | 0.82 | RARA (0.44) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL12309424 | 0.81 | HIF1A (0.41) | RARARARBRARGLMNAKMT2A | |
| SCHEMBL5828203 | 0.80 | RARA (0.35) | RARARARBRARGLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210869-A1 | New method for the preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | Galderma Research & Development (FR) | 2010-07-28 | — | — | EP | claimed |
| EP-1868980-B1 | NEW METHOD FOR THE PREPARATION OF 6-(3-(1-ADAMANTYL)-4-METHOXPHENYL)-2-NAPHTHOIC ACID | GALDERMA RES & DEV (FR) | 2010-07-28 | — | — | EP | claimed |
| EP-1993986-B1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | FINORGA SAS (FR) | 2010-07-14 | — | — | EP | claimed |
| US-20100010265-A1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | COMELY ALEXANDER CHRISTIAN | 2010-01-14 | — | — | US | claimed |
| US-20090137841-A1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | FINORGA SAS (FR) | 2009-05-28 | — | — | US | claimed |
| US-7498461-B2 | Method for the preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-03 | — | — | US | claimed |
| EP-1993986-A1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | FINORGA SAS (FR) | 2008-11-26 | — | — | EP | claimed |
| EP-1986985-A1 | INTERMEDIATES AND PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | FINORGA SAS (FR) | 2008-11-05 | — | — | EP | claimed |
| US-20080091045-A1 | Novel method for the preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-04-17 | — | — | US | claimed |
| EP-1868980-A2 | NEW METHOD FOR THE PREPARATION OF 6-(3-(1-ADAMANTYL)-4-METHOXPHENYL)-2-NAPHTHOIC ACID | Galderma Research & Development (FR) | 2007-12-26 | — | — | EP | claimed |
| WO-2007063522-A1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | FINORGA SAS (FR) | 2007-06-07 | — | — | WO | claimed |
| WO-2007063523-A1 | INTERMEDIATES AND PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | FINORGA SAS (FR) | 2007-06-07 | — | — | WO | claimed |
| WO-2006108717-A2 | NEW METHOD FOR THE PREPARATION OF 6-(3-(1-ADAMANTYL)-4-METHOXPHENYL)-2-NAPHTHOIC ACID | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-19 | — | — | WO | claimed |
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | SPECIAL PRODUCTS LINE S P A (IT) | 2026-02-05 | — | — | US | disclosed |
| US-20230346727-A1 | COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA | UNIVERSITE GRENOBLE ALPES (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-4083029-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003011808-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMORAL AND PROAPOPTOTIC ACTIVITIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346727-A1 | COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA | PROC, F2, F8 | RARA 1675/4885RARB 1848/4885RARG 1713/4885 |
| US-20100010265-A1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | AMD1, CYP51A1, DDC | RARA 757/4885RARB 1157/4885RARG 1838/4885 |
| US-20080091045-A1 | Novel method for the preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | CYP2B6, CYP2A6, CYP26B1 | RARA 238/4885RARB 269/4885RARG 1057/4885 |
| US-20090137841-A1 | PROCESS FOR THE PREPARATION OF AROMATIC DERIVATIVES OF 1-ADAMANTANE | AMD1, CYP51A1, DDC | RARA 757/4885RARB 1157/4885RARG 1838/4885 |
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | TLR7, GANC, ARG1 | RARA 2620/4885RARB 2413/4885RARG 2152/4885 |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | RARA 1460/4885RARB 1465/4885RARG 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.